Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256937 | 1.00 | AVPR2 (0.70) | AVPR2AVPR1A | |
| SCHEMBL256933 | 1.00 | AVPR2 (0.70) | AVPR2AVPR1A | |
| SCHEMBL23765088 | 0.91 | AVPR2 (0.60) | AVPR2AVPR1A | |
| SCHEMBL22365876 | 0.91 | AVPR2 (0.60) | AVPR2AVPR1A | |
| SCHEMBL19574619 | 0.89 | AVPR2 (0.59) | AVPR2AVPR1A | |
| SCHEMBL19574618 | 0.89 | AVPR2 (0.59) | AVPR2AVPR1A | |
| SCHEMBL19551158 | 0.89 | AVPR2 (0.57) | AVPR2AVPR1A | |
| SCHEMBL19551180 | 0.89 | AVPR2 (0.57) | AVPR2AVPR1A | |
| SCHEMBL19551194 | 0.89 | AVPR2 (0.57) | AVPR2AVPR1A | |
| SCHEMBL13158519 | 0.88 | AVPR2 (0.60) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-17 | — | — | US | disclosed |
| US-10927098-B2 | Hydroxyalkyl-substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10815205-B2 | Amide-substituted phenyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-10-27 | — | — | US | disclosed |
| US-10800746-B2 | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3452457-B1 | OXOALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma AG (DE) | 2020-03-18 | — | — | EP | disclosed |
| US-10472348-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-11-12 | — | — | US | disclosed |
| US-20190315720-A1 | HYDROXYALKYL-SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | US | disclosed |
| US-20190161454-A1 | AMIDE-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20190161453-A1 | OXOALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-30 | — | — | US | disclosed |
| US-20190142804-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-16 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| WO-2011104322-A1 | BISARYL-BONDED ARYLTRIAZOLONES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011023703-A1 | HETEROCYCLIC-SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | WO | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927098-B2 | Hydroxyalkyl-substituted triazole derivatives and uses thereof | LIPG, PLIN3, FABP3 | AVPR2 2546/4885AVPR1A 3882/4885 |
| US-20190161453-A1 | OXOALKYL-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | AADAC, REN, PKD1 | AVPR2 1542/4885AVPR1A 3160/4885 |
| US-10472348-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | AADAC, GLS, PDXK | AVPR2 1068/4885AVPR1A 2095/4885 |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885 |
| US-10815205-B2 | Amide-substituted phenyltriazole derivatives and uses thereof | AADAC, GLS, NAT1 | AVPR2 665/4885AVPR1A 2027/4885 |
| US-10800746-B2 | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof | AADAC, REN, PKD1 | AVPR2 1542/4885AVPR1A 3160/4885 |
| US-20190161454-A1 | AMIDE-SUBSTITUTED PHENYLTRIAZOLE DERIVATIVES AND USES THEREOF | AADAC, GLS, NAT1 | AVPR2 665/4885AVPR1A 2027/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885 |
| US-20190315720-A1 | HYDROXYALKYL-SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | LIPG, PLIN3, FABP3 | AVPR2 2546/4885AVPR1A 3882/4885 |
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | AADAC, GLS, PDXK | AVPR2 1068/4885AVPR1A 2095/4885 |
| US-20190142804-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | AADAC, NAT1, FABP3 | AVPR2 3453/4885AVPR1A 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.